Abstract:Zhejiang Children's Hospital (ZCH)-2B8a antibody was recently generated in our laboratory using leukemia cell line KG1a as immunogen. This antibody was submitted to the 8th International Workshop and Conference on Human Leukocyte Differentiation Antigens (HLDA8) and the results showed that the antibody recognized an unknown molecule on the surface of some blood cells. In this study, the reactivity of the antibody on normal and malignant hematopoietic cells was investigated and its diagnostic and therapeutic significances were explored. Materials and Methods 3 specimens each of normal peripheral blood, bone marrow/G-CSF mobilized peripheral blood CD34+ stem/progenitor cells (PBSCs), 13 hematopoietic cell lines and the cells from 100 leukemia patients (male 58: female 42, 33 cases of children and 67 adults, aged 11 month ~ 77 yrs) were enrolled into this study. A multi-parameter flow cytometry with CD45 gating strategy was used to analyze the cells. Results 2B8a weakly reacted with a few B lymphocytes (34.3±15.91%), monocytes(44.4±37.77%), granulocytes (26.4±22.40%), but not reacted with other blood cells such as T cells (0.6±0.37%), NK cells (2.6±1.56%), DC cells (8.4±8.18%), erythrocytes (0.4±0.21%) and platelets (0.3±0.28%). It was reactive with 38.0±9.09% of bone marrow CD34+ cells with 21.0±22.00% of CD38+ and 25.3±22.6% of CD38- subsets (P = 0.5). In G-CSF mobilized PBSCs, 2B8a recognized 11.7±18.73% of CD34+ PBSCs with 9.7±15.20% of CD38+ and 33.3±57.74% of CD38- subsets. The positive rates of 2B8a on a panel of hematopoietic cell lines were shown in Table 1. The fresh leukemia cell analysis showed that the antibody primarily reacted with lymphoid leukemias, of which acute lymphocytic leukemia (ALL) and chronic lymphocytic leukemia (CLL) accounted for 29%(9/31) and 40%(2/5), respectively. It did not react with most cases of myeloid leukemias, with only 5%(3/57) of acute myeloid leukemia(AML) and 0% (0/6) of chronic myelogeneous leukemia (CML) cases, in which significant difference between myeloid and lymphoid leukemias (χ2 = 10.29, P < 0.01) was found; In ALL, 2B8a only reacted with B lineage (32%, 9/28), while not with T and NK lineage leukemias. In B lineage leukemia, early Pre-B ALL was the most reactive type of disease, positive in 60% of cases, significantly higher than cALL cases (5/21, 24%, P = 0.0173) with declining expression pattern with cell maturation. There was no reactivity in mature B-ALL but it was strongly reactive with lymphoma cells suggesting the possibility for this antibody as a potential targeting therapy for patients with B lineage lymphoma. Conclusions 2B8a may be used in distinguishing lymphoid from myeloid leukemia. It might hold a potential application for targeting therapy for patients with leukemia and malignant lymphoma. (This work was supported by the grant (No. 398427) from Zhejiang Provincial Scientific Fundation).

[Epitopes Recognized by Cytotoxic T Lymphocytes in Immunoglobulin Heavy Chain Variable Regions Expressed by B-cell Acute Lymphoblastic Leukemia].

[Characteristics of Immunoglobulin Heavy Chain Variable Region Genes in Childhood B-cell Acute Lymphoblastic Leukemia].

[Proliferation of Specific Cytotoxic T Lymphocytes Induced by Immunoglobulin Heavy Chain Framework Region-Derived Antigenic Nonapeptides].

Generation of Cytotoxic T Lymphocytes Specific for B-cell Acute Lymphoblastic Leukemia Family-Shared Peptides Derived from Immunoglobulin Heavy Chain Framework Region

Induction of anti B-cell malignance CTL response by subfamily-shared peptides derived from variable domain of immunoglobulin heavy chain

[Induction of Anti-B-cell Acute Lymphoblastic Leukemia Cytotoxic T Lymphocyte Response Against Immunoglobulin Heavy Chain Frame-Derived Nonapeptide].

Induction Of Potent Anti-B-Cell Lymphoma Ctl Responses By The Same Immunoglobulin Variable Region Subfamily Framework-Derived Peptides.

Identification of predicted epitopes of HLA-A * 0201-restricted cytotoxic T lymphocytes derived from human papillomavirus type 11 E7 antigen

[Function analysis of the family-specific CTL induced by peptides derived from IgHV gene framework region of B-cell malignance].

Significance of Clonal Gene Rearrangements of Immunoglobulin Heavy Chain and T-cell Receptor Γ in Acute Nonlymphoblastic Leukemia

[The characteristics of anti-B-cell malignance cytotoxic T lymphocytic clones induced by lymphoma relative peptides].

Characteristics of malignant clone from acute lymphocytic leukemia]

Reactivity Of A Novel Antibody Zch-2b8a On Normal And Malignant Hematopoietic Cells.

Vaccination with Immunoglobulin Frame Region-Derived Nonapeptide Elicits Cellular Immune Response Against Lymphoma in Human Leukocyte Antigen-A2.1 Transgenic Mice

B cell lymphoproliferative disorders and VH4-34 gene encoded antibodies

[Cloning and Sequencing of VL and VH Genes from a Novel Clone ZCH-7-2F9 of Anti-Hcd14 Monoclonal Antibody].

Detection of Clonal Lymphoid Receptor Gene Rearrangements in Langerhans Cell Histiocytosis

[Analysis of mutations in IgVH genes in diffuse large B-cell lymphomas].

Next-Generation Sequencing Revealed a Distinct Immunoglobulin Repertoire with Specific Mutation Hotspots in Acute Myeloid Leukemia

Clonality Analysis and Mutational Status of IgVH Gene in Hodgkin Variant of Richter Syndrome

[A Genetic Analysis of Children with Epstein-Barr Virus-Positive Hemophagocytic Lymphohistiocytosis and Its Association with T-helper Type 1/T-Helper Type 2 Cytokines].